Gezielt nachschlagen
Suche
Suche startet nach einer kurzen Eingabepause.
20 angezeigte Treffer · Seite 6, keine Gesamtzahl für „Strong“
Suchtreffer
Begriffe & Kennungen
Brukinsa · 4.5 · If a strong CYP3A inhibitor must be used (e.g., voriconazole, ketoconazole, itraconazole, clarithromycin, indi
Eintrag öffnenBrukinsa · 4.5 · If a strong CYP3A inhibitor must be used (e.g., voriconazole, ketoconazole, itraconazole, clarithromycin, indi
Eintrag öffnenBrukinsa · 4.5 · Strong CYP3A inhibitors
Eintrag öffnenBrukinsa · 4.5 · Strong CYP3A inhibitors
Eintrag öffnenBrukinsa · 4.5 · The coadministration of multiple doses of itraconazole (strong CYP3A inhibitor) in healthy volunteers increase
Eintrag öffnenBrukinsa · 4.5 · The coadministration of multiple doses of itraconazole (strong CYP3A inhibitor) in healthy volunteers increase
Eintrag öffnenCabazitaxel Accord · 4.5 · CYP3A inducers Repeated administration of rifampin (600 mg once daily), a strong CYP3A inducer, resulted in an
Eintrag öffnenCabazitaxel Accord · 4.5 · CYP3A inhibitors Repeated administration of ketoconazole (400 mg once daily), a strong CYP3A inhibitor, result
Eintrag öffnenCabometyx · 4.5 · Administration of the strong CYP3A4 inducer rifampicin (600 mg daily for 31 days) to healthy volunteers increa
Eintrag öffnenCabometyx · 4.5 · CYP3A4 inhibitors and inducers Administration of the strong CYP3A4 inhibitor ketoconazole (400 mg daily for 27
Eintrag öffnenCalquence · 4.5 · Co--administration of a strong CYP3A inducer (600 mg rifampicin once daily for 9 days) decreased acalabrutinib
Eintrag öffnenCalquence · 4.5 · Co-administration of a strong CYP3A inducer (600 mg rifampicin once daily for 9 days) decreased acalabrutinib
Eintrag öffnenCalquence · 4.5 · Co-administration with a strong CYP3A/P-gp inhibitor (200 mg itraconazole once daily for 5 days) increased aca
Eintrag öffnenCalquence · 4.5 · Co-administration with a strong CYP3A/P-gp inhibitor (200 mg itraconazole once daily for 5 days) increased aca
Eintrag öffnenCalquence · 4.5 · Concomitant use with strong CYP3A/P-gp inhibitors should be avoided. If the strong CYP3A/P-gp inhibitors (e.g.
Eintrag öffnenCalquence · 4.5 · Concomitant use with strong CYP3A/P-gp inhibitors should be avoided. If the strong CYP3A/P-gp inhibitors (e.g.
Eintrag öffnenCalquence · 4.5 · Concomitant use with strong inducers of CYP3A activity (e.g., phenytoin, rifampicin, carbamazepine) should be
Eintrag öffnenCalquence · 4.5 · Concomitant use with strong inducers of CYP3A activity (e.g., phenytoin, rifampicin, carbamazepine) should be
Eintrag öffnenCamzyos · 4.5 · CYP2C19 inhibitors The effect of a moderate and strong CYP2C19 inhibitor on the PK of mavacamten was not inves
Eintrag öffnenCamzyos · 4.5 · CYP3A4 inhibitors The effect of strong CYP3A4 inhibitors on the PK of mavacamten was not investigated in a cli
Eintrag öffnen